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500Cord Blood Units with Low CD341 Cell Viability Have
a Low Probability of Engraftment after Double Unit
Transplantation
Andromachi Scaradavou,1 Katherine M. Smith,2 Rebecca Hawke,3 Allison Schaible,2
Michelle Abboud,4 Nancy A. Kernan,1 James W. Young,3 Juliet N. Barker3Double unit cord blood (CB) transplantation (CBT) appears to augment engraftment despite only one unit
engrafting inmostpatients.Wehypothesized that superior unit quality, asmeasuredby ahigherpercentageof viable
cells postthaw, would determine the engrafting unit. Therefore, we prospectively analyzed 46 double-unit trans-
plants postthaw using flow cytometry with modified gating that included all dead cells. Using a 75% threshold
(mean viability minus 2 SD), 20% of units had low CD341 cell viability, with viability varying according to the
bankof origin. Further, in the 44 patients with single unit engraftment, CD341 cell viability was higher in engrafting
units (P5.0016). Although either unit engrafted if both had high CD341 viability, units with\75% viability were
very unlikely to engraft: in 16 patients who received one high and one low CD341 viability unit, only 1 of 16 units
with viability\75%engrafted (P5.0006). Further, in the single patientwithout engraftment of either unit, both had
CD341 viability\75%. Finally, poorCD341 viability correlatedwith lower colony forming units (CFUs) (P5.02).
Our data suggests one mechanism by which double unit CBT can improve engraftment is by increasing the prob-
ability of transplanting at least one unit with adequate viability and the potential to engraft.
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Although cord blood (CB) is increasingly used as
an alternative hematopoietic stem cell (HSC) source
that promises to extend transplant access to patients
of racial and ethnic minorities, low total nucleated
cell (TNC) dose is often limiting [1-4]. Double unit
CB transplantation (CBT) can frequently overcome
the cell dose limitations of single unit grafts in adults
and large children [5-10]. This strategy improves
engraftment compared with historic controls, despite
only one unit giving rise to donor hematopoiesis in
most patients [8]. Further, preliminary data suggest
that the double unit approach may be associated with
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6/j.bbmt.2009.11.013mechanisms that determine engraftment and unit pre-
dominance are of great interest, but have not been elu-
cidated. Previous studies have compared the infused
doses of TNC, CD341 progenitors, or CD31 T cells
of the two units. Although one study found an associa-
tion between higher CD31 cell dose and the engrafting
unit [8], this variable did not predict engraftment in in-
dividual patients. We hypothesized that superior unit
quality, as measured by a higher percentage of viable
cells postthaw, would determine the engrafting unit
in double unit CBT. Processing, freezing, storage,
transport, or thawing of a unit can damage CB cells
at any point, and evaluation of cell numbers alone can-
not accurately assess the degree of injury. We hypoth-
esized that the proportion of dead cells in a unit reflects
the degree of damage to the entire unit. Therefore, we
evaluated the effect of viability (percent viable cells) of
CB cell subpopulations (CD451, CD341, and CD31
cells) postthaw on unit engraftment, in a prospective
series of 46 consecutive double unit CBT recipients.METHODS
Patients and Treatment Plan
All CBT recipients or their parents signed in-
formed consent before transplantation. Patients had
a median age of 37 years (range: 7-65 years) and
Biol Blood Marrow Transplant 16:500-508, 2010 501CD341 Viability in Double Unit CB Transplantamedian weight of 72 kg (range: 22-109). All had high-
risk hematologic malignancies: acute myelogenous
leukemia (AML; N5 11), acute lymphoblastic leuke-
mia (ALL; N5 6), acute biphenotypic leukemia
(N5 2), non-Hodgkin lymphoma (NHL; N5 14),
Hodgkin lymphoma (HL; N5 9), chronic lympho-
cytic leukemia (CLL; N5 3), and prolymphocytic leu-
kemia (N5 1). Conditioning was myeloablative (MA;
N5 31) or nonmyeloablative (NMA; N5 15) accord-
ing to age, diagnosis, extent of prior therapy, and co-
morbidities, with all regimens including fludarabine
(Flu). All patients received immunosuppression with
cyclosporine A (CsA) and mycophenolate mofetil
(MMF), and engraftment support with posttransplant
granulocyte-colony stimulating factor (G-CSF). Re-
cipients of a prior allogeneic transplant were not in-
cluded in this study.
CB Unit Selection
CB units were selected according to TNC dose
and HLA match, and were obtained from domestic
(N5 71) and international CB banks (N5 21 units).
CB units were matched to the patient at 4-6/6 HLA-
A,-B antigens, and -DRB1 alleles [6/6 (N5 5, 5%),
5/6 (N5 42, 46%), and 4/6 (N5 45, 49%)]. HLA-
matching between the 2 units was 6/6 (N5 2), 5/6
(N5 11), 4/6 (N5 18), 3/6 (N5 12), and 2/6
(N5 3). High-resolution HLA typing at HLA-A, -B,
-C, -DRB1, and -DQB1 alleles was performed on all
patients and donor units, although the allele matching
of loci other than HLA-DRB1 was usually not consid-
ered in unit selection. The donor-recipient HLA-
match at high resolution ranged from 2-9/10. All
patients received double unit grafts. The larger unit
had a median infused TNC dose of 2.5 107/kg
(range: 1.4-4.5), and the smaller had a median TNC
of 1.9 107/kg (range: 0.9-3.7).
CB Unit Thaw and Infusion
Initially units were thawed with albumin-dextran
dilution followed by centrifugation [13]. However, in
an effort to reduce cell loss and unit manipulation, we
subsequently changed our thaw strategy to a dilution
without centrifugation for CBT recipients $20 kg
[14]. Hence, the majority of CB units (N5 83, 90%)
were thawed using the ‘‘no-wash’’ technique, whereas
9 CB units were thawed and washed with centrifuga-
tion. Units were infused within 2 hours of thawing
with an interval of less than 45 minutes between the
infusion of the first and second unit.
Postthaw Evaluations
Postthaw TNC
Postthaw TNC count was obtained using an auto-
mated hematology Coulter counter. Nucleated cellviability was assessed by trypan blue exclusion as per
standard laboratory procedures.
Flow cytometric evaluation
Four-color flow cytometric evaluation of the CB
units was performed using a FACSCalibur flow cytom-
eter (Becton Dickinson Biosciences, San Jose, CA) and
CellQuest Pro software (BD Biosciences). Samples for
flow cytometric analysis were taken from the final
product prior to its release to the transplant floor and
were stained within 1 hour of thaw. Duplicate aliquots
containing 0.5 106CBcellswere incubatedwith anti-
CD45 FITC (BD #340664), anti-CD34 PE (Beckman
Coulter #IM1871), and anti-CD3 APC (BD #340661)
at room temperature in the dark for 20 minutes. Red
blood cells (RBCs) were lysed with fixative-free ammo-
nium chloride (10NH4Cl Lysing Solution, Beck-
man Coulter #IM3514, diluted with reagent grade
water to 1). 7-Amino-actinomycin D (7AAD) (Beck-
man Coulter #IM3422) was then added. Samples were
vortexed, kept at room temperature in the dark for
15 minutes, and then stored for\1 hour on wet ice in
the dark until acquisition. Because most units under-
went albumin-dextran dilution, and cells were not
washed during the staining, dead cells were not
removed at any step during sample preparation.
Flow cytometric evaluation was performed using
the International Society of Hematotherapy and Graft
Engineering (ISHAGE) gating strategy [15] with sev-
eral modifications to maximize the detection of live
and dead cells. Compensations were set to avoid spec-
tral overlap for CD34 PE and 7AAD. This was
achieved by initially determining the appropriate
photo multiplier tube (PMT) and compensation set-
tings and then periodically checking the compensation
settings with single stains. Heat killed or lysed cells
were used to establish the 7AAD compensation, and
compensation settings were confirmed with each
sample by checking 2-color dot plots.
Although the essentials of the ISHAGE sequential
gating strategy were retained, we lowered the forward
scatter (FSC) threshold to include all 7AAD-positive
dead cells and viewed the 7AAD versus FSC instead
of the traditional 7AAD versus side scatter (SSC) dot
plot. More debris was acquired with the lowered
FSC threshold, but this was easily excluded with the
modified 7AAD versus FSC dot plot because debris
is 7AAD-negative with a lower FSC than cells. There-
fore, a ‘‘Not Debris’’ region can be set so that debris is
excluded from all subsequent dot plots. In figure 1A,
plot 1 shows the FSC versus SSC dot plot in which
the FSC primary threshold was adjusted to exclude
most debris and RBC, but not the dead cells. Similarly,
the FL1 secondary threshold was adjusted on the
CD45 FITC versus SSC dot plot to exclude most
red cells, platelets, and other debris but not any
CD451 cells (not shown). The sequential Boolean
Figure 1. Flow cytometric evaluation of CB units postthaw. Live cells are shown in green, dead cells are shown in red, and debris is shown in black. (A)
Modified gating strategy. Plot 1: the lower FSC primary threshold excludes most debris but no dead cells. Plot 2: viability is assessed in the FSC versus
7AAD dot plot. Debris is shown in R6 and is gated out in all subsequent plots. Dead cells (7AAD-positive) are in R7 whereas live cells (7AAD-negative)
are in R5. Plot 3: for comparison traditional gating cannot adequately distinguish debris from viable cells in the 7AAD versus SSC dot plot. Live and dead
cells are shown for CD451 (Plot 4), CD341 (Plot 5), and CD31 (Plot 6) cell populations. Viability was calculated from the total debris-free sample for
CD451 cells (Plot 7), CD341 cells (Plot 8), and CD31 cells (Plot 9). An average of 300 events (range: 100-1000) were acquired per sample for the
CD341 cell analysis. (B) Traditional gating strategy. The same plots as in A are shown with a high FSC threshold that excludes most dead cells, as fre-
quently used in traditional gating. In CB units with a high percentage of dead cells the traditional methodology overestimates cell viability compared with
our modified gating. (C) Comparison of CD341 cell viability using modified and traditional gating in CB units with a small percentage of dead cells. The
difference between the 2 gating strategies is small.
502 Biol Blood Marrow Transplant 16:500-508, 2010A. Scaradavou et al.gating strategy as defined by ISHAGE was then ap-
plied to identify CD341 cells. Specifically, we gated
on CD341 antigen expression, followed by a gate onCD451 low to intermediate antigen expression with
fluorescence intensity characteristic of blast cells, and
finally we set an FSC versus SSC gate with low SSC
Figure 1. (continued).
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cytes and blast cells. We assured that the lower bound-
ary of the lymphoblast gate included the smallest
lymphocytes. In this sequential gating strategy, mono-
cytes are excluded because they express high levels of
CD45 and increased SSC in comparison with true
CD341 cells, whereas granulocytes are excluded be-
cause they exhibitmarkedly higher SSC characteristics.
Viability was then evaluated on the FSC versus
7AAD dot plot (Figure 1A, Plot 2) instead of the tradi-
tional SSC versus 7AAD plot (shown in Figure 1A,
Plot 3 for comparison). In our modified gating strategy
shown in Figure 1A, Plot 2, to more clearly distinguish
dead cells from debris, events were gated to encompass
all 7AAD-negative (viable) cells in region 5 (R5), all
7AAD-positive (dead) cells in R7, and all low FSC
7AAD-negative debris in R6. Live and dead cells were
evaluated as shown for CD451 (Figure 1A, Plot 4),
CD341 (Figure 1A, Plot 5), and CD31 (Figure 1A,
Plot 6) cell populations. Notably, Figure 1A, Plot 5,
clearly shows that theCD341 cells are lowSSC.Viability
was calculated from the total debris-free sample for
CD451 cells (Figure 1A, Plot 7), CD341 cells
(Figure 1A, Plot 8), and CD31 cells (Figure 1A, Plot 9).
Initially, we performed isoclonic (CD341) and isotype
(CD31) controls, but, because of the multiparameter
gating usingBoolean logic, theywere found to be redun-
dant, and were abandoned as recommended byGratama
et al. [16] and Keeney et al. [17]. Periodically, we stain
controls to assure that nonspecific staining is minimal.
Our modified gating strategy allowed the acquisi-
tion of all dead (7AAD-positive) cells and viable
(7AAD-negative) cells so that viability was determined
from the total, debris-free populations. Figure 1Bdemonstrates the overestimation of the percent viabil-
ity by traditional gating compared with the modified
gating strategy in Figure 1A. This is especially evident
in units with many dead cells as shown in this example.
In contrast, both traditional and modified gating strat-
egies resulted in similar CD341 viabilities in CB units
with few dead cells, as shown in Figure 1C. Absolute
CD341 and CD31 cell numbers were determined
using the two-platform method.
Colony-forming unit (CFU) assays
CFU assays were performed on all CB units using
a total of 1 105 cells plated in duplicate. Colony
growth was evaluated by light microscopy at 14 days.
Engraftment, Donor Chimerism, and Unit
Predominance
Neutrophil engraftment was defined as the first of
3 consecutive days of an absolute neutrophil count
(ANC) $0.5 109/L after the posttransplant nadir.
Serial sampling of the bone marrow (BM) and/ or pe-
ripheral blood (PB) at days 21, 28, 60, 100, 180, and
360 after transplantation determined donor chimerism
using quantitative polymerase chain reaction of infor-
mative polymorphic DNA short tandem repeats
(STR) in recipient anddonor units (GenePrint Fluores-
cent STRMarkerKit, Promega,Madison,WI) [8]. The
engrafting unit contributed .50% of the total donor
chimerism in serial testing.
Statistical Analysis
Statistical analyses were performed using SPSS
(v12.0, Chicago, IL) or Excel software. A value of
a
w
CD34+ cells CD3+ cells CD45+ cells
100
90
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variables were estimated by chi-square and between
means by the Student t-test (paired).P
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Figure 2. Postthaw CD341, CD31, and CD451 cell viability and unit
engraftment in 44 double unit CB grafts. The distribution of postthaw
viabilities of the CD341, CD31, and CD451 cells are shown for the
engrafting (in closed symbols) and nonengrafting units (open symbols)
for the 44 patients with single unit engraftment.RESULTS
Engraftment and Donor Chimerism
Forty-five of the 46 patients (98%) had donor en-
graftment in the BM by DNA analysis on day 21 post-
transplant. One unit engrafted in 44 of these 45
patients, whereas a single patient had sustained en-
graftment of both units. The single patient without en-
graftment of either unit received NMA conditioning
and had autologous recovery.
The median donor chimerism of the engrafting
unit was 100% in recipients of MA conditioning at all
time points tested. Recipients of NMA conditioning
initially had mixed donor-host chimerism because of
transient recovery of autologous hematopoiesis but at-
tained 100% donor with the engrafting unit by day 60.
Although a minority of patients had a small contribu-
tion from the nonengrafting unit early after transplant,
the median percent chimerism of the nonengrafting
unit was 0% at all time points with both types of
conditioning.
Of the 45 patients with donor engraftment by
DNA analysis, 43 had donor-derived neutrophil recov-
ery with a median time to absolute neutrophil count
(ANC) $0.5 109/L of 25 days (range: 13-38) after
MA and 11 days (range: 7-36) after NMA condition-
ing. The 2 patients who engrafted by DNA analysis
but did not have sustained neutrophil recovery re-
ceived MA conditioning and suffered lethal infections
early posttransplant. One developed Staphylococcus au-
reus septicemia on day 7, and the other had cytomega-
lovirus (CMV) disease at day 20. One additional
patient, also a recipient of MA conditioning, had sec-
ondary graft failure in the setting of human herpes vi-
rus (HHV)-6 infection.Table 1. Analysis of CD34+ and CD3+ Cell Viability Thresh-
olds for Unit Engraftment
CD34+ Cell Viability
of Engrafting CB Unit Viability Threshold P-Value
Mean viability 88.0% .56
Mean—SD 81.5% .016
Mean—2SD 75.0% .0006
Mean—3SD 68.5% .048
CD3+ Cell Viability
of Engrafting CB Unit Viability Threshold P-Value
Mean viability 84.0% .15
Mean2 SD 73.4% .039
Mean2 2SD 62.8% .11
Mean2 3SD 52.2% .048Postthaw CD341 Cell Viability and Unit
Engraftment
Figure 2 depicts the flow cytometric cell viabilities
of the engrafting and nonengrafting units in the 44 pa-
tients with single unit engraftment in the BM. The
mean CD341 cell viability of the 44 units that
engrafted in these patients was 88% (SD5 6.5%).
CD341 cell viability was significantly higher in the en-
grafting units (P5 .0016), and units with a high propor-
tion of dead cells (ie, low viability) did not engraft. The
numbers of engrafting and nonengrafting units were
compared at various viability thresholds using a chi-
squared analysis (Table 1). A clear distinction was seen
at a CD341 viability threshold of 75%, which repre-
sented 2 SDs below themean of the overall distribution.Among the 44 patients (88 units) with engraftment of
a single unit, 16 received grafts consisting of one high
and one low viability unit. In these 16 patients only 1
of 16 (6%) units with CD341 cell viability\75% en-
grafted. In the other 28 patients, both units had viability
over 75% and either engrafted. Thus, in these patients
with engraftment of a single unit, 43 of 72 (60%) en-
grafted with a unit with high viability (Table 2). Nota-
bly, the single patient without evidence of any donor
hematopoiesis posttransplant received two units, each
ofwhichhadCD341 viability\75%(74%and36%, re-
spectively). Thus, overall, only 1 of 18 units (6%) with
CD341 viability \75% engrafted. The patient with
stable engraftment of both units received two units
with CD341 viability$75% (both were 86%).
CD31 cell viability correlated with CD341 cell vi-
ability (R25 0.47, p\ .01) and with unit engraftment
(p5 .0077). The mean CD31 cell viability of the en-
grafting units was 84% (SD5 10.6%). An analysis
was performed comparing the number of engrafting
and nonengrafting CB units, using similar viability
Table 2. PostthawCD34+ Cell Viability andUnit Engraftment
in 44 Recipients (88 Units) of Double Unit CB Grafts Who
Engrafted with a Single Unit
% CD34+ Cell
Viability
Engrafting
CB Unit (N, %)
Nonengrafting
CB Unit (N, %)
<75% 1 (6%) 15 (94%)
$75% 43 (61%) 29 (39%)
All units 44 (50%) 44 (50%)
Themean postthawCD34+ cell viability for the engrafting units was 88%,
SD was 6.5%. Using CD34+ viability of 75% (ie, mean2 2SD), all but 1 of
the engrafting units had CD34+ cell viability $75% (P5.0006). The
single patient with engraftment of both units (both with high viability)
is excluded.
Biol Blood Marrow Transplant 16:500-508, 2010 505CD341 Viability in Double Unit CB Transplantthresholds of CD31 cells as for CD341 cells, but the
results were not highly significant (Table 1). CD451
viability correlated weakly with CD341 cell viability
(R25 0.3, P \ .01). There was no difference in
CD451 cell viability between the units that engrafted
and those that did not (P5 .07). Moreover, postthaw
evaluation of nucleated cells by trypan blue exclusion
had no correlation with CD341 cell viability
(R25 .008) or unit engraftment (P5NS).
Postthaw CD341 cell viability correlated with
postthaw total CFU output. CB units with CD341
cell viability $75% had a significantly higher median
total CFU of 224 (range: 18-722) compared to units
with CD341 cell viability \75% that had a lower
median total CFU of 118 (range: 1-493) (P5 .02).
Figure 3 shows the postthaw CD341 cell viability
of all CB units used in the study (N5 92) according
to the CB bank of origin. Although units of high viabil-
ity were obtained from both domestic and interna-
tional banks, viability of units varied between banks
with some banks (both domestic and international)
providing a disproportionate number of low viability
units. We did not detect a difference in CD341 viabil-
ity according to the method of thaw (data not shown).100
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Figure 3. Postthaw CD341 cell viability and CB bank of origin (N5 92
units). CB units were obtained from domestic (N5 71), and interna-
tional banks (INT, N5 21). Each group depicts the distribution of viabil-
ity for the respective units from each bank (for the domestic) or each
country (for the international ones).Other Graft Characteristics and Unit
Engraftment
Infused cell and CFU doses were examined for
their relationship with engraftment in the 44 patients
with engraftment of a single unit (Table 3). As in pre-
vious analyses of double unit engraftment [8], the
absolute numbers of infused TNC/kg and infused via-
ble CD341 progenitor cells/kg were not associated
with unit engraftment in univariate analyses. Engrafting
units had significantly higher infused viableCD31 cells/
kg (P5 .03), although the absolute CD31 cells/kg
dose did not always predict the engrafting unit in in-
dividual patients. CFU/kg and CFU-GM/kg were
not associated with the engrafting unit except in 1
patient where 1 of the 2 units had no CFU growth
and failed to engraft [18].
Also as previously reported [8], donor-recipient
HLA-matching at HLA-A, -B antigens and -DRB1 al-
leles was not associated with unit engraftment in this
study. In the 44 patients with single unit engraftment,
12 received units with different HLAmatch levels, and
the better matched unit engrafted in only 3 cases. Each
unit differed in the donor-recipient HLA-A, -B, -C,
-DRB1, and -DQ allele match in 25 patients. The bet-
ter HLA-matched unit engrafted in only 10 of them
(P5NS). Notably, however, the patient with sus-
tained engraftment of both donors received units
that were each 9/10 HLA-matched to the recipient
and to each other (each had a single mismatch at
HLA-A). This was the only patient who received units
so closely matched by high resolution HLA typing.
Finally, the order of unit infusion did not predict
the engrafting unit. Of the 44 patients who had donor
hematopoiesis from a single unit, the engrafting unit
was infused first in 23 and second in 21 patients
(P5NS).DISCUSSION
We prospectively investigated the correlates of do-
nor engraftment after double unit CBT in 46 consec-
utive patients. In contrast to the traditional gating
where dead cells can be excluded [15], we used modi-
fied flow cytometric gating that excludes onlyTable 3. Postthaw Mean Cell Doses in Engrafting and
Nonengrafting Units of the 44 Double Unit CBT Recipients
with Single Unit Engraftment
Engrafting
CB Unit
Nonengrafting
CB Unit P-Value
Infused TNC/kg (107) 2.2 2.2 .90
Infused viable CD34+/kg (105) 1.1 0.9 .13
Infused viable CD3+/kg (105) 38.6 31.4 .03
CFU/kg (104) 3.7 3.2 .31
CFU-GM/kg (104) 1.6 1.5 .90
CFU-GM indicates colony-forming unit, granulocyte macrophage; TNC,
total nucleated cell; CB, cord blood.
90% 
viability
50%
viability
Total CD34
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Figure 4. Schema depicting the difference between the dose of viable
CD341 cells/kg versus the percentage of viable CD341 cells in 2 CB
units. The infused viable CD341 cells per kg of the recipient weight
(CD341 cell dose) and the percent CD341 cell viability (7AAD-positive
CD341 cells divided by the total CD341 cells in the unit expressed as
a percentage) represent 2 different graft characteristics. In this example
the 2 CB units have the same total number of viable CD341 cells (and
would have an identical infused CD341 cell dose). However, the per-
centage of viable CD341 cells is markedly different. Based on the results
of this study unit, #1 is of poor quality and we would predict that unit #2
would engraft in the double unit setting.
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and dead cells. With this methodology, an approach
that is appropriate for the assessment of all cryopre-
served hematopoietic products, all dead cells in the
graft are counted, and therefore the proportions of
dead and live cells can be calculated precisely. Using
this modified gating strategy we showed significant
differences in the postthaw viabilities of CD341 and
CD31 cells between engrafting and nonengrafting
CB units. Although it is unclear how widely flow based
viability has been adopted by transplant centers, the
modification of traditional gating to incorporate
a 7AAD viability analysis has previously been reported
[19,20]. Further, the potential clinical importance of
measuring the viable cell dose has been appreciated
when administering hematopoietic grafts such as do-
nor lymphocytes [21]. However, the significance of
the percentage of viable cells in a cryopreserved prod-
uct as a surrogate of product quality is a novel finding.
We found the percentage of viable CD341 cells as
measured by the modified gating, but not the infused
CD341 dose/kg, proved to be the most critical deter-
minant of the engraftment potential of a CB unit in
double unit CBT (Figure 2, and Tables 1 and 2).
This concept can be explained by the example in
Figure 4 where two units with similar absolute
CD341 cell doses/kg differ widely in their percentages
of viable CD341 cells and thus their quality. Units
with a low percentage of viable CD341 cells have
had a significant proportion of the CD341 cells de-
stroyed. The remaining cells, although viable as deter-
mined by 7AAD staining, are likely also damaged,
thereby compromising the engraftment potential of
the entire unit. The correlation of percent CD341
cell viability with the respective values of CD451 and
CD31 cell viability support this hypothesis, as does
the association between lower CFU counts and units
with poor CD341 cell viability.
We, therefore, propose that double unit CBT in-
creases the probability that the patient will receive at
least one unit with adequate viability and thus with
the potential to engraft. To facilitate clinical decisions,
however, an appropriate viability ‘‘threshold’’ is
needed. Using 75% viability, which represented the
mean of the CD341 distribution minus 2 SD, had
clinical utility as units with CD341 cell viability below
75% had a low probability of engraftment (P5 .0006).
In fact, only 1 of the 18 units with CD341 cell viability
\75% engrafted. Using this threshold a further major
finding of our study was that low viability units were
not uncommon: 18/ 92 (20%) hadCD341 cell viability
\75%. This percentage is similar to the incidence of
graft failure reported in many series of single unit
CBT (reviewed in [22,23]). Therefore, although the
significance of viability in single unit CBT cannot be
determined from this study, the correlation of viability
and engraftment in single unit CBT is of great interest.We are not able to evaluate this as in an attempt to aug-
ment engraftment, and possibly protect against relapse
[11,12], we have only performed CBT using double
unit grafts to date.
It is intriguing to hypothesize that the only unit
with CD341 cell viability \75% that engrafted in
our study may have sustained a different type of injury
than the others. It is also likely that engraftment may
be influenced by additional factors such as the infused
TNC dose. Units with a very high TNC dose may en-
graft despite low CD341 cell viability if they contain
sufficient numbers of unaffected cells. Our patients re-
ceived only a mean TNC dose of 2.2 107/kg
(SD5 0.69). Thus, the effect of lowCD341 cell viabil-
ity on the engraftment of high cell dose units could not
be evaluated.
Our findings highlight the importance of CB unit
quality and have significant implications for both CB
banks and transplant centers. Notably, not only did
we find variable viability from unit to unit, we also
found marked differences in the CD341 cell viability
of units obtained from different individual CB banks
(Figure 3),with some banks providing a disproportion-
ate number of low viability units. This was despite the
fact that units were stored in a uniform manner at our
center and likely indicates the extent to which varying
bank practices may alter product quality, and could not
be attributed to shipping distance because many inter-
national units had high viability. What specific bank-
ing practices could lead to this finding could not be
analyzed, as this information is not provided to the
transplant centers. Future studies involving both banks
Biol Blood Marrow Transplant 16:500-508, 2010 507CD341 Viability in Double Unit CB Transplantand transplant centers need to investigate the events
that could adversely affect viability during CB collec-
tion, processing, cryopreservation, long-term storage,
and transport, as well as short-term storage at the
transplant center. Criteria of product quality also
merit standardization and implementation to optimize
the global CB inventory.
These findings also have multiple ramifications for
transplant centers. Centers must determine how they
will assess unit quality andwhat threshold is acceptable.
Based on the results of this study we now define an ad-
equate graft as two units with at least one with CD341
cell viability$75%. Our findings have prompted us to
performdouble unit transplants exclusively atMSKCC
to date as the risk of having a single unit graft with poor
viability on the day of transplant is not acceptable given
the challenging logistics of urgently obtaining a second
unit, which may not be readily available.
Although this analysis demonstrated that units
with low CD341 viability are very unlikely to engraft,
it does not elucidate the mechanism of CB unit pre-
dominance when both units of a double unit graft
have high viability. In this scenario, we postulate that
either unit has the potential to engraft, and that im-
mune mediated phenomena may dictate engraftment.
This is supported by the engrafting unit having
a higher CD31 dose/kg in this analysis, as previously
reported, as well as preliminary results of transplants
in immunodeficient mice given aliquots from each
unit of our patient’s grafts as single unit grafts and in
combination [24]. Further, it is interesting that the sin-
gle patient with stable mixed donor engraftment was
the only one who received two units with high viability
that were both also unusually highly matched at 9/10
HLA-alleles to the patient and to each other. We pro-
pose that in this case each unit had engraftment poten-
tial, but each was tolerant of the other, permitting
coengraftment.
In summary, units with low viability, and thus poor
quality, are very unlikely to engraft in double unit
CBT. Centers should ensure that at least one of the
units of the graft has a significant proportion of viable
CD341 and CD31 cells, without depending on trypan
blue exclusion or traditional ISHAGE gating for eval-
uation of unit quality. Our viability assay is easily per-
formed and available on transplant day, in contrast to
CFU assay results that require 2 additional weeks. In
the future, it would be preferable that a similar assay
could be used to evaluate viability postcryopreserva-
tion, but prior to unit thaw, using the cells from an at-
tached segment for example. Development of such an
approach should be amajor priority.Moreover, our re-
sults merit investigation in larger patient series of both
single and double unit transplants in the multicenter
setting. Important aspects of these studies will be the
standardization of the CD341 cell viability assay, the
effect of the thaw method (wash versus no wash) onthe accurate calculation of dead versus viable cells,
and whether transplantation with high-quality units
speeds neutrophil and platelet engraftment.ACKNOWLEDGMENTS
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